What is ApoB discordance and why does standard LDL-C miss it?

ApoB discordance occurs when a patient's ApoB particle count is elevated despite normal or low LDL-C. This is driven by small, dense LDL particles common in insulin resistance and hypertriglyceridemia. Because each atherogenic particle contains exactly one ApoB molecule, ApoB accurately reflects true arterial particle exposure.

What is an optimal Triglyceride to HDL ratio?

A TG/HDL ratio under 2.0 indicates optimal insulin sensitivity and predominantly large, buoyant LDL particles. A ratio between 2.0 and 3.0 indicates borderline insulin resistance, while a ratio above 3.0 strongly correlates with atherogenic dyslipidemia and small dense LDL particles.

Can diet lower Lipoprotein(a) [Lp(a)] levels?

No. Lipoprotein(a) levels are 80-90% genetically determined by the LPA gene. Standard diet, exercise, and traditional statins do not significantly lower Lp(a). Identifying elevated Lp(a) (>125 nmol/L) requires aggressive management of all other modifiable risk factors and lowering ApoB below 55 mg/dL.

ADVANCED METABOLIC LIPIDOMICS

Beyond Total Cholesterol: Precision Atherogenic Risk

Evaluate particle number (ApoB), atherogenic particle density (TG/HDL ratio), and independent genetic risk (Lp(a)) using validated cardiovascular medicine equations.

ApoB Particle Count:88 mg/dL

Triglycerides / HDL:2.40 (Borderline)

Lp(a) Genetic Factor:28 nmol/L

STEP 01 // COMPREHENSIVE BIOMARKERS

Input Beyond Standard Total Cholesterol

Standard panels miss up to 40% of high-risk patients. Our engine takes ApoB, LDL-C, HDL-C, Triglycerides, and Lp(a) to compute true atherogenic exposure.

DISCORDANCE ALERT

Normal LDL-C (105 mg/dL) vs Elevated ApoB (118 mg/dL)

Small dense LDL particles present. Each particle can penetrate arterial intima.

STEP 02 // ALGORITHMIC IDENTIFICATION

Unmask Masked Atherogenic Plaque Risk

When triglycerides are elevated, cholesteryl ester transfers create smaller, dense LDL particles. Standard LDL-C looks reassuring, while particle count (ApoB) is severely elevated.

ACTIONABLE PROTOCOL

Target: ApoB < 55 mg/dL

Lifestyle + Statin/Ezetimibe/PCSK9i + Direct Lab Requisition

STEP 03 // EVIDENCE-BASED INTERVENTION

Clear Target Thresholds & Lab Access

Get immediate stratification based on ACC/AHA & ESC 2026 guidelines. Don't have your ApoB or Lp(a)? Order direct without doctor requisition.

PANEL INPUTS

Serum Lipid Profile (mg/dL)

Apolipoprotein B (ApoB)

mg/dL

Target: < 65 mg/dL (High risk) | < 80 (Moderate)

LDL Cholesterol (LDL-C)

mg/dL

Target: < 70 mg/dL (High risk) | < 100 (Optimal)

HDL Cholesterol (HDL-C)

mg/dL

Protective: > 50 mg/dL (M) / > 60 (F)

Serum Triglycerides (TG)

mg/dL

Optimal: < 100 mg/dL | Normal: < 150

Lipoprotein(a) [Lp(a)]

nmol/L

Normal: < 75 nmol/L | Elevated: > 125

High-Sensitivity CRP (hs-CRP)

mg/L

Low Risk: < 1.0 | High Inflammation: > 3.0

CLINICAL STRATIFICATION

Cardiovascular Risk Index

TG / HDL-C Ratio

2.40

Borderline Insulin Resistance

Non-HDL Cholesterol

135 mg/dL

Above Target (< 100)

Particle Discordance

Discordant (Low LDL / High ApoB)

True Risk Underestimated by LDL-C

Lp(a) Genetic Threat

Normal (28 nmol/L)

No Independent Genetic Elevation

Evidence-Based Clinical Takeaway:

Prioritize lowering ApoB below 70 mg/dL using lifestyle and lipid-lowering therapy. The TG/HDL ratio indicates visceral adiposity or hepatic insulin resistance driving small dense LDL formation.

DIRECT LAB REQUISITION From $37.00 • No Referral Needed

Order Your ApoB, Lp(a) & Cardio IQ Panel

Don't have your current numbers? Skip the doctor's appointment. Order physician-approved requisitions direct to Quest Diagnostics or Labcorp nationwide.

Order Quest / Labcorp Blood Panel →

✓ 100% Confidential • HSA/FSA Eligible • Results in 48h

LONGEVITY MEDICINE DISPATCH

Download the ApoB Discordance & ASCVD Decision Matrix

Join 12,000+ physicians, researchers, and proactive patients receiving our evidence-based breakdowns of clinical lipidology trials, PCSK9i therapy, and dietary protocols.

PHYSIOLOGY & PATHOLOGY

Why ApoB Trumps Standard LDL-C

Every atherogenic particle (LDL, VLDL, IDL, Lp(a)) contains exactly one molecule of Apolipoprotein B100.

The Passenger vs. Car Analogy

LDL-C measures the total weight of cholesterol inside the particles (the passengers). ApoB measures the exact particle count (the cars on the road). Atherosclerosis is driven by particle collisions with the arterial intima, not the weight of cargo inside.

Insulin Resistance & Small Dense LDL

When serum triglycerides are elevated, cholesteryl ester transfer protein (CETP) exchanges core lipids, generating smaller, cholesterol-depleted LDL particles. Standard LDL-C appears normal while true particle count (ApoB) spikes catastrophically.

Lp(a): The Silent Genetic Hazard

Lipoprotein(a) is an LDL particle bound to apolipoprotein(a). Highly thrombogenic and atherogenic, 80-90% of Lp(a) levels are genetically determined by the LPA gene and do not respond to diet or statins alone.

CONSENSUS GUIDELINES

Target Biomarker Thresholds

Biomarker	Primary Prevention (Optimal)	Moderate Risk (Target)	Very High Risk (Secondary Prev.)	Primary Clinical Society
ApoB (mg/dL)	< 80	< 70	< 55	ESC / NLA / AHA
LDL-C (mg/dL)	< 100	< 70	< 55	ACC / AHA 2024
Non-HDL-C (mg/dL)	< 130	< 100	< 85	AHA / NLA
TG / HDL-C Ratio	< 1.5	< 2.5	< 3.0	Metabolic Consensus
Lp(a) (nmol/L)	< 75	< 75	< 75 (Independent)	National Lipid Assoc.

PARADIGM COMPARISON

Standard Cholesterol vs. Precision Lipidomics

Why modern cardiology is moving decisively beyond basic Friedewald total cholesterol panels.

Diagnostic Dimension	Standard Lipid Profile (Status Quo)	Precision Biomarker OS (lipids.dev)	Clinical Advantage
Primary Measurement	Cholesterol Mass (Weight inside particles)	Particle Number (ApoB Molecule Count)	Direct measure of arterial wall collisions
Small Dense LDL Detection	✗ Invisible (Masked by low LDL-C)	✓ Detected via TG/HDL & Discordance	Catches metabolic syndrome & insulin resistance early
Genetic Thrombosis Risk	✗ Not Measured (Lp(a) omitted)	✓ Independent Lp(a) Stratification	Uncovers high-risk familial heart disease
Intervention Target	Vague "Eat Less Saturated Fat"	Evidence Threshold: ApoB < 55 mg/dL	Targeted pharmacotherapy & nutritional precision

FREQUENTLY ASKED QUESTIONS

Clinical Biomarkers & Atherogenic Plaque

Answers to common questions regarding ApoB discordance, lab tests, and cardiovascular risk.

ApoB discordance occurs when particle count is elevated while cholesterol concentration looks normal. Because patients with high triglycerides or insulin resistance carry smaller, cholesterol-depleted LDL particles, a standard LDL-C test undercounts the number of particles penetrating arterial walls. ApoB provides the true, unambiguous count of all atherogenic particles.

A ratio under 2.0 (calculated in mg/dL) indicates optimal insulin sensitivity and a favorable pattern of large, buoyant LDL particles. A ratio between 2.0 and 3.0 suggests emerging insulin resistance, while a ratio greater than 3.0 strongly correlates with atherogenic dyslipidemia and small dense LDL.

No. Approximately 80% to 90% of circulating Lp(a) levels are determined genetically by the LPA gene. Diet, exercise, and standard statins do not produce significant reductions. When Lp(a) is elevated (>125 nmol/L), the clinical consensus is to aggressively lower all other modifiable risk factors—most notably driving ApoB below 55 mg/dL.

No. Direct-to-consumer lab services (such as Ulta Lab Tests or Marek Diagnostics) allow you to order physician-approved requisitions online for Quest Diagnostics or Labcorp without an in-person doctor visit. Tests are cash-pay, generally HSA/FSA eligible, and deliver results within 48 to 72 hours.